FHTX241220C7500
- 0.48
- -1.26-72.41%
Foghorn Therapeutics Newsroom
TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
Foghorn Therapeutics Analyst Ratings
Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating
Jefferies Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $18
Foghorn Therapeutics Analyst Ratings
Evercore Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)
Evercore Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $20
Foghorn Therapeutics Drug Candidates FHD-286 and FHD-909 Show Promise in Early Trials, Justifying Buy Rating
Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $13 Price Target
Foghorn Therapeutics Analyst Ratings
Wedbush Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)
Foghorn Therapeutics Analyst Ratings
Foghorn Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Stryker (SYK), Foghorn Therapeutics (FHTX)
Foghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliances